• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian

    9/10/25 6:32:50 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NRXS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Miranda Adrian

    (Last) (First) (Middle)
    11611 N. MERIDIAN ST,
    SUITE 330

    (Street)
    CARMEL IN 46032

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Neuraxis, INC [ NRXS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CMO, SVP Science & Tech
    3. Date of Earliest Transaction (Month/Day/Year)
    01/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    RSU (1) 03/04/2025 A 10,000 (1) (1) Common Stock 10,000 $2.18 10,000 D
    RSU (2) 03/04/2025 A 30,000 (2) (2) Common Stock 30,000 $2.18 30,000 D
    RSU (3) 01/03/2025 A 35,000 (3) (3) Common Stock 35,000 $2.42 35,000 D
    Explanation of Responses:
    1. These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.
    2. These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.
    3. These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months.
    /s/ Adrian Miranda 09/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NRXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Carrico Brian Allen

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:56 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:53 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Ferge Kristin A was granted 13,157 shares, increasing direct ownership by 1,112% to 14,340 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:54 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain

    CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that it has been awarded a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract, effective December 1, 2025. The first product listed on the FSS is the IB-Stim®, a drug-free treatment for functional abdominal pain in patients 8 years and older. This contract award establishes NeurAxis as a federal contractor and creates a clear commercial pathway into the VA health system, which serves nearly 7 million active patients annually. T

    12/1/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives

    CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric beneficiaries in Michigan now have access to PENFS under medical policy. This expansion increases NeurAxis' total national coverage to roughly 55 million total lives, with additional payer decisions from major i

    11/12/25 8:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues

    CARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2025. 3Q25 Financial highlights Revenues increased 22% year over year to $811 thousand in 3Q25 compared to $667 thousand in 3Q24.Operating loss in 3Q25 increased 27% year over year compared to 3Q24 due to increased sales and marketing efforts.Cash balance was $4.4 million as of September 30, 2025. Subsequently, the Company secured an additional $2.8 million through an at-the-mar

    11/11/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.

    SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)

    11/12/25 8:27:21 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Neuraxis Inc.

    10-Q - Neuraxis, INC (0001933567) (Filer)

    11/10/25 5:01:18 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Neuraxis, INC (0001933567) (Filer)

    10/24/25 8:22:36 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hannasch Brian bought $800,001 worth of shares (355,556 units at $2.25), increasing direct ownership by 46% to 1,131,522 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    7/3/25 11:24:27 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Hannasch Brian bought $31,251 worth of shares (18,065 units at $1.73), increasing direct ownership by 2% to 775,966 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    4/23/25 4:38:50 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Leadership Updates

    Live Leadership Updates

    View All

    NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

    CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable

    1/31/24 9:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Financials

    Live finance-specific insights

    View All

    NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025

    CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its third quarter 2025, for the period ended September 30, 2025, on Tuesday, November 11, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 11, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, November 11, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live we

    11/4/25 8:30:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

    CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on

    8/12/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

    CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, whi

    8/5/25 8:30:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuraxis Inc.

    SC 13D - Neuraxis, INC (0001933567) (Subject)

    12/2/24 11:53:07 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Neuraxis Inc.

    SC 13G - Neuraxis, INC (0001933567) (Subject)

    12/2/24 9:57:28 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

    SC 13G/A - Neuraxis, INC (0001933567) (Subject)

    10/8/24 7:30:11 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care